Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 185,162 shares of the biopharmaceutical company’s stock after buying an additional 19,800 shares during the quarter. Renaissance Technologies LLC owned about 0.17% of Regeneron Pharmaceuticals worth $194,611,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. SteelPeak Wealth LLC increased its stake in Regeneron Pharmaceuticals by 173.0% in the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock valued at $1,148,000 after purchasing an additional 692 shares in the last quarter. Atria Investments Inc increased its stake in Regeneron Pharmaceuticals by 12.2% in the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after purchasing an additional 941 shares in the last quarter. Nordea Investment Management AB increased its stake in Regeneron Pharmaceuticals by 23.2% in the 1st quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock valued at $28,218,000 after purchasing an additional 5,495 shares in the last quarter. Tidal Investments LLC increased its position in Regeneron Pharmaceuticals by 16.8% during the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after buying an additional 711 shares in the last quarter. Finally, Sierra Summit Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth $1,011,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 1.0 %

REGN stock opened at $1,153.35 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20. The company has a 50-day moving average of $1,124.22 and a two-hundred day moving average of $1,026.46. The stock has a market capitalization of $127.08 billion, a price-to-earnings ratio of 34.07, a price-to-earnings-growth ratio of 3.97 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter last year, the company earned $8.79 earnings per share. The firm’s revenue was up 12.3% on a year-over-year basis. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on REGN shares. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, September 9th. JPMorgan Chase & Co. lifted their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $1,250.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, September 5th. Barclays lifted their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Finally, Guggenheim lifted their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,109.70.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,026 shares of company stock worth $11,498,705. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.